Positron emission tomography imaging of oestrogen receptor-expression in endometrial stromal sarcoma supports oestrogen receptor-targeted therapy: Case report and review of the literature

European Journal of Cancer

Volumn 49, Issue 18, 2013, Pages 3850-3855

  Van Kruchten, Michel ^a   Hospers, Geke A P ^a   Glaudemans, Andor W J M ^a   Hollema, Harry ^a   Arts, Henriëtte J G ^a   Reyners, Anna K L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Endocrine therapy; Endometrial stromal sarcoma; FES PET; Fulvestrant; Oestrogen receptor

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; FLUOROESTRADIOL F 18; FULVESTRANT; MEGESTROL ACETATE; RADIOPHARMACEUTICAL AGENT; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DRUG WITHDRAWAL; ENDOMETRIUM SARCOMA; FEMALE; HUMAN; PRIORITY JOURNAL;

ENDOCRINE THERAPY; ENDOMETRIAL STROMAL SARCOMA; FES PET; FULVESTRANT; OESTROGEN RECEPTOR;

ADULT; ENDOMETRIAL NEOPLASMS; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, ESTROGEN; SARCOMA, ENDOMETRIAL STROMAL; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84888016115     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.08.005     Document Type: Article

References (44)

1. D. Boll, R.H. Verhoeven, and M.A. van der Aa Incidence and survival trends of uncommon corpus uteri malignancies in the Netherlands, 1989-2008 Int J Gynecol Cancer 22 2012 599 606
2. E. D'Angelo, L.G. Spagnoli, and J. Prat Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system Hum Pathol 40 2009 1571 1585
3. K.L. Chang, G.S. Crabtree, S.K. Lim-Tan, R.L. Kempson, and M.R. Hendrickson Primary uterine endometrial stromal neoplasms. A clinicopathologic study of 117 cases Am J Surg Pathol 14 1990 415 438
4. J.K. Chan, N.M. Kawar, and J.Y. Shin Endometrial stromal sarcoma: a population-based analysis Br J Cancer 99 2008 1210 1215
5. F. Amant, A. Coosemans, M. Debiec-Rychter, D. Timmerman, and I. Vergote Clinical management of uterine sarcomas Lancet Oncol 10 2009 1188 1198
6. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology; Uterine Neoplasms v1.2013; 2013. Available from http://www.nccn.org/professionals/physician-gls/pdf/uterine.pdf [accessed 27.02.13].
7. M.C. Chu, G. Mor, C. Lim, W. Zheng, V. Parkash, and P.E. Schwartz Low-grade endometrial stromal sarcoma: hormonal aspects Gynecol Oncol 90 2003 170 176
8. Y. Kitaoka, J. Kitawaki, and H. Koshiba Aromatase cytochrome P450 and estrogen and progesterone receptors in uterine sarcomas: correlation with clinical parameters J Steroid Biochem Mol Biol 88 2004 183 189
9. D. Pink, T. Lindner, and A. Mrozek Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature Gynecol Oncol 101 2006 464 469
10. F. Amant, A. De Knijf, and B. Van Calster Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma Br J Cancer 97 2007 1194 1199
11. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
12. M. van Kruchten, A.W. Glaudemans, and E.F. de Vries PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma J Nucl Med 53 2012 182 190
13. R. Boellaard, M.J. O'Doherty, and W.A. Weber FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 Eur J Nucl Med Mol Imaging 37 2010 181 200
14. F.C. Maluf, P. Sabbatini, L. Schwartz, J. Xia, and C. Aghajanian Endometrial stromal sarcoma: objective response to letrozole Gynecol Oncol 82 2001 384 388
15. M. Ihnen, S. Mahner, F. Janicke, and J. Schwarz Current treatment options in uterine endometrial stromal sarcoma: report of a case and review of the literature Int J Gynecol Cancer 17 2007 957 963
16. M. Leunen, M. Breugelmans, P. De Sutter, C. Bourgain, and J.J. Amy Low-grade endometrial stromal sarcoma treated with the aromatase inhibitor letrozole Gynecol Oncol 95 2004 769 771
17. A.D. Altman, G.S. Nelson, P. Chu, J. Nation, and P. Ghatage Uterine sarcoma and aromatase inhibitors: Tom Baker Cancer Centre experience and review of the literature Int J Gynecol Cancer 22 2012 1006 1012
18. T. Dahhan, G. Fons, M.R. Buist, F.J. Ten Kate, and J. van der Velden The efficacy of hormonal treatment for residual or recurrent low-grade endometrial stromal sarcoma. A retrospective study Eur J Obstet Gynecol Reprod Biol 144 2009 80 84
19. Y.J. Ioffe, A.J. Li, and C.S. Walsh Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles Gynecol Oncol 115 2009 466 471
20. K. Krauss, C. Bachmann, and J.T. Hartmann Management of late recurrence of a low-grade endometrial stromal sarcoma (LGESS): treatment with letrozole Anticancer Res 27 2007 3477 3480
21. V. Landreat, N. Paillocher, L. Catala, F. Foucher, P. Descamps, and J. Leveque Low-grade endometrial stromal sarcoma of the uterus: review of 10 cases Anticancer Res 28 2008 2869 2874
22. K. Shoji, K. Oda, and S. Nakagawa Aromatase inhibitor anastrozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case report Med Oncol 28 2011 771 774
23. E. Tzakas, S. Liu, R.W. Todd, and C.W. Redman Hormonal therapy with letrozole prior to surgical management of recurrent metastatic low-grade endometrial stromal sarcoma (LGESS) J Obstet Gynaecol 29 2009 778 779
24. M. Beresford, I. Tumur, J. Chakrabarti, J. Barden, N. Rao, and A. Makris A qualitative systematic review of the evidence base for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic breast cancer Clin Oncol (R Coll Radiol) 23 2011 209 215
25. D.K. Wysowski, S.F. Honig, and J. Beitz Uterine sarcoma associated with tamoxifen use N Engl J Med 346 2002 1832 1833
26. G. Le Bouedec, H. Auvray, H. Cure, M. de Latour, F. Penault-Llorca, and J. Dauplat Uterine sarcoma in patients receiving tamoxifen therapy. Apropos of 2 cases Rev Med Intern 22 2001 881 885
27. B. Fisher, J.P. Costantino, C.K. Redmond, E.R. Fisher, D.L. Wickerham, and W.M. Cronin Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 J Natl Cancer Inst 86 1994 527 537
28. D.L. Wickerham, B. Fisher, and N. Wolmark Association of tamoxifen and uterine sarcoma J Clin Oncol 20 2002 2758 2760
29. L. Bergman, M.L. Beelen, M.P. Gallee, H. Hollema, J. Benraadt, and F.E. van Leeuwen Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen Lancet 356 2000 881 887
30. T.W. Beer, R. Buchanan, and C.H. Buckley Uterine stromal sarcoma following tamoxifen treatment J Clin Pathol 48 1995 596
31. B.L. Riggs, and L.C. Hartmann Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice N Engl J Med 348 2003 618 629
32. Y. Shang, and M. Brown Molecular determinants for the tissue specificity of SERMs Science 295 2002 2465 2468
33. A. Howell Pure estrogen antagonists for the treatment of advanced breast cancer Endocr Relat Cancer 13 2006 689 706
34. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) C. Davies, and J. Godwin Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Lancet 378 2011 771 784
35. van Kruchten M, de Vries EG, Brown M, et al. PET imaging of oestrogen receptors in patients with breast cancer. Lancet Oncol 2013 [in press].
36. 18F- fluoroestradiol J Nucl Med 49 2008 367 374
37. J.E. Mortimer, F. Dehdashti, B.A. Siegel, K. Trinkaus, J.A. Katzenellenbogen, and M.J. Welch Metabolic flare: indicator of hormone responsiveness in advanced breast cancer J Clin Oncol 19 2001 2797 2803
38. H.M. Linden, S.A. Stekhova, and J.M. Link Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer J Clin Oncol 24 2006 2793 2799
39. F. Dehdashti, J.E. Mortimer, and K. Trinkaus PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer Breast Cancer Res Treat 113 2009 509 517
40. Y. Ohta, T. Suzuki, and M. Omatsu Transition from low-grade endometrial stromal sarcoma to high-grade endometrial stromal sarcoma Int J Gynecol Pathol 29 2010 374 377
41. E. Amir, N. Miller, and W. Geddie Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer J Clin Oncol 30 2012 587 592
42. G.G. Chung, M.P. Zerkowski, S. Ghosh, R.L. Camp, and D.L. Rimm Quantitative analysis of estrogen receptor heterogeneity in breast cancer Lab Invest 87 2007 662 669
43. L.J. Layfield, E. Saria, E.E. Mooney, K. Liu, and R.R. Dodge Tissue heterogeneity of immunohistochemically detected estrogen receptor. Implications for image analysis quantification Am J Clin Pathol 110 1998 758 764
44. M.E. Hammond, D.F. Hayes, and M. Dowsett American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer J Clin Oncol 28 2010 2784 2795